 Daxor Corporation NYSE American: DXR Daxor or the Company, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 140,352 shares of its common stock at a price of 14.25 per share, for aggregate gross proceeds of approximately 2.0 million, in a registered direct offering priced at-the-market. The Company intends to use the net proceeds for working capital and other general corporate purposes. H.C. Wainwright Co. is acting as exclusive placement agent for the offering. 